Paradoxical Worsening of Eczematous Cutaneous Immune-Related Adverse Events Associated with Dupilumab: Two Cases
Clicks: 3
ID: 317644
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #105 of 176 articles by views in clinical and experimental dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 176 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
This letter presents two cases of patients with immune checkpoint inhibitor-induced eczematous cutaneous immune-related adverse events (cirAEs) who experienced rapid and severe paradoxical worsening following dupilumab administration. Both patients achieved clinical improvement with methotrexate-based therapy, with short-course systemic corticosteroids added when needed, while anticancer therapy was maintained and no tumour progression was observed during follow-up. These findings highlight the need for cautious use of dupilumab in cirAE patients under immune checkpoint inhibitor treatment, and suggest that conventional systemic agents remain important options when balancing cutaneous toxicity control with continuity of cancer treatment.
| Reference Key |
openalex_W7165047317
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yuchen Shen, J Huang, Lujuan Gao, Yi Sun, Weiduo Chen, Shuyan Dong, Wenxi Li, Jie Yang |
| Journal | clinical and experimental dermatology |
| Year | 2026 |
| DOI |
10.1093/ced/llag249
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.